Matwings reported that laboratory measurements guided the selection of subsequent protein variants for the GenSci148 drug candidate

Matwings reported that laboratory measurements guided the selection of subsequent protein variants for the GenSci148 drug candidate

On August 20, Matwings reported completing four development cycles for GenSci148, a protein drug candidate for retinal diseases. AI proposed new protein variants, the laboratory tested them, and the results informed the next selection of variants and the properties targeted for improvement.

Binding to the intended target is not enough for a protein to become a drug. The molecule must remain stable, be suitable for production, and form a solution that can be administered. Each laboratory round in this program therefore addressed two questions: which variants should be developed next, and which properties should be tested.

In its August 20 press release, Matwings states that the teams tested 222 protein variants over four rounds: 92 in the first round, 30 in the second, and 50 in each of the third and fourth rounds. The first two rounds focused on biological activity, meaning whether the protein performed the intended function. The third and fourth rounds also assessed the viscosity of the concentrated solution, which determines how thick the drug formulation will be, along with other properties relevant to development.

The company reports that the results from each round informed the next design iteration. Laboratory measurements shaped two decisions at once: which set of protein variants to create next and which requirements those variants should meet.

GenSci148 is a candidate for treating retinal diseases. The GenSci page states that the Chinese drug regulator authorized clinical trials of the candidate for three such diseases. The four rounds described by Matwings were part of this program.